Post Reply
421-440 of 5066
No dead i still alive😅
tofudidi ( Date: 16-Apr-2026 13:05) Posted:
|
shortist dead?
Now still in loss how to go up high? Too hyper that why. Mayne once hyper no more it will go down fast let see
piscesmonkey ( Date: 16-Apr-2026 12:09) Posted:
|
Yes if break 430 i going cut
easywin ( Date: 16-Apr-2026 12:03) Posted:
|
Some turbulence once clear 0.435 than shortists know the game well
2nd round short at 420. 1round was covered at 400
Elf2000 ( Date: 16-Apr-2026 11:33) Posted:
|
Where are the scaremongers? Mute again?
As mentioned, I expect IX BioPharma to turn green at the end of this trading day.
Don' t anyhow react to msg from shortists - they were meant to frighten you.
Understand the business, the prodcts, the potential.
Understand what the company is doing and how the business is to be run.
As far as I know, share price still long way to go...$1??
Don' t anyhow react to msg from shortists - they were meant to frighten you.
Understand the business, the prodcts, the potential.
Understand what the company is doing and how the business is to be run.
As far as I know, share price still long way to go...$1??
Sibehboeng ( Date: 16-Apr-2026 10:36) Posted:
|
After 425 than likely 500 on the way soon
Share price of iX Biopharma briefly hits IPO price of 46 cents after listing on Catalist board for 11 years
After 11 years of listing, iX Biopharma&rsquo s share price finally recovered back to its IPO price during today&rsquo s trading session and currently has a market cap of around $438 million.
Back in July 2015, iX Biopharma was listed on the Catalist board with an IPO price of 46 cents. The IPO allowed the pharmaceutical company to raise some $30 million in proceeds.
However, just one year ago, iX Biopharma&rsquo s share price was trading at a near-distressed level of around 1.5 cents per share.
Since then, its share price has miraculously shot up by more than 2,200% across the same period. That means that based on a $1,000 investment in iX Biopharma one year ago, investors today can expect a return of more than $22,000.
Some of the contributing factors for this strong run-up can be attributed to the participation of institution investors such as Lion Global Investors and Ginko-AGT Global Growth Fund for their November 2025 placement and the latest US Department of Defense (DoD) US$40.95 million contract to fund the development of Wafermine.
More importantly, iX Biopharma is back on analysts&rsquo radar yet again. On April 10, Phillip Securities&rsquo research head Paul Chew re-initiated coverage on iX Biopharma with a &ldquo buy&rdquo call and $1 price target.
From his perspective, Chew believes that the recent US$40.95 million Phase 3 clinical trial funding and orders from the US DoD are a major endorsement and major external validation of the WaferiX sublingual technology.
Following his call, share price gained 65% and closed at 33 cents on the same day of his re-initiation report, with 130 million shares changing hands. In the following days ahead, share price saw a further gain of 28%.
As of 4pm, shares in iX Biopharma were unchanged at 42.5 cents.
iX Biopharma&rsquo s Lee and wife Tang sell 13 mil shares on two different occasions
Eddy Lee Yip Hang, executive chairman of iX Biopharma (SGX:42C) , and his wife, Jane Tang Choy Leng, sold 13 million shares in the company on April 10 and April 13.
On April 10, Lee sold 10 million shares via married deal for a total consideration of $2.6 million. This translates to an average price of 26 cents each.
Interestingly, Lee on April 8 exercised his warrants and was allotted 10 million new ordinary shares at a price of 6 cents per warrant.
With the disposal, Lee has pocketed a profit of $2 million and lowered his shareholding interest in iX Biopharma down to 22.874%.
On April 13, Tang sold 3 million shares via market transaction for a total consideration of $1,047,750. This translates to an average price of 34.93 cents each.
As a result, this further lowered Lee&rsquo s shareholding interest in the company to 22.588%.
Earlier today, iX Biopharma&rsquo s share price hit an intra-day high of 46 cents, which is equivalent to its IPO price back in July 2015.
Shares of iX Biopharma closed flat at 42.5 cents. For the past one year, its share price saw a gain of more than 2,000%.
Thanks, appreciate the gesture.
Caesar ( Date: 16-Apr-2026 11:07) Posted:
|
Now 40.5c. congrats ...maybe later back to 42.5c? Me not vested, just giving moral support
ahberngh ( Date: 16-Apr-2026 10:25) Posted:
|
No worries bro... is common, those who bought long will sing praises and potential to go higher, those who have shorted now will scare everyone to sell... reader just use own judgement
ahberngh ( Date: 16-Apr-2026 10:30) Posted:
|
not much volume liao.. exit 1st.. come back later
short squeeze?
Just my opinion, no offence to anyone.
ahberngh ( Date: 16-Apr-2026 10:29) Posted:
|
Just because the CEO wanted to take back some spending money, shortists and speculators
try to scare people.
Those weak holders who sell, better move somehere else
.
try to scare people.
Those weak holders who sell, better move somehere else
.
Those bought below 30c still not yet finished taking profits? Huge force selling volumes coming..🧐 🤨
Bought at 40c and 38.5c.